logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Pharmaceutical Intermediates > [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium Bromide CAS 154057-58-6

[2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium Bromide CAS 154057-58-6

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 154057-58-6

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum/Plastic bottles, Plastic buckets

Delivery Time: 7-15DAY

Payment Terms: D/A,L/C,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:

CAS 154057-58-6 Quinolin-3-ylmethyl

,

Triphenyl-phosphonium Bromide Quinolin-3-ylmethyl

CAS NO::
154057-58-6
Appearance::
Powder Or Liquid
Molecular Formula::
C37H30BrFNP
Molecular Weight::
618.51700
EINECS NO::
NA
MDL NO::
MFCD19440813
CAS NO::
154057-58-6
Appearance::
Powder Or Liquid
Molecular Formula::
C37H30BrFNP
Molecular Weight::
618.51700
EINECS NO::
NA
MDL NO::
MFCD19440813
[2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium Bromide CAS 154057-58-6

Product Description:

Product Name: [2-Cyclopropyl-4-(4-fluorophenyl)-quinolin-3-ylmethyl]-triphenyl-phosphonium bromide CAS NO: 154057-58-6


Synonyms:

((2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)methyl)triphenylphosphonium bromide;

[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]methyl-triphenylphosphanium,bromide;

 

Chemical & Physical Properties:

Appearance: Powder or liquid

Assay :≥99.00%

Melting Point: 218-225℃


Safety Information:

Signal Word: Warning

Precautionary Statements: P261-P305 P351 P338

Hazard Statements: H315-H319-H335


The mechanism of action of pitvastatin calcium intermediates is currently believed to be that they inhibit the rate-limiting enzyme in the early stage of intracellular cholesterol synthesis, namely HMG-COA reductase, reduce the intracellular free cholesterol, and then feed the expression of low density lipoprotein (LDL) receptor on the cell surface, and increase the number and activity of LDL receptor. It accelerates the removal of very low density lipoprotein (VLDL) residues or medium density lipoprotein (IDL) and LDL from circulating blood. In addition, it also inhibits the synthesis of VLDL in the liver, significantly reduces total cholesterol (TC) and LDL-C, but also reduces triglyceride (TG) and increases high-density lipoprotein cholesterol (HDL-C).


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.